NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Yiwu Aozuo Trading Co

Published 12 Nov 2026. 33-page investigative report on who is behind Yiwu Aozuo Trading Co: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Yiwu Aozuo is not a one-score vendor. Across 149 Finnrick lab tests the overall pass rate is 79% (117 pass / 32 fail), but the catalog splits sharply. Tirzepatide and GHK-Cu are the best-supported Aozuo categories; Retatrutide is usable only as an exact-batch-verification buy; Sermorelin is the clearest avoid signal. The full charts also show where ratings lose confidence under stricter grading assumptions.

The identity trail is younger and messier than the storefront copy suggests. Aozuo-branded domains, a Shenzhen corporate capture, a Yiwu sales address, a .cn service-provider registrant, and a removed GlobalSources profile point to a 2024-2025 export-trading footprint, not a corroborated 10+ year peptide manufacturer. No public GMP certificate, facility audit, QA lead, or batch-release authority was found in the reviewed material, so oversight cannot be verified from public sources.

Aozuo has real lab-side evidence: public Janoshik records tie Yiwu Aozuo Trading Firm to an Aozuo-controlled global storefront and show strong results for selected Tirzepatide/Retatrutide batches. The gap is buyer verification. The vendor gallery is stuck on older image uploads, the global site carries template debris and a placeholder filing string, and buyers must reconcile domain, salesperson, payment recipient, vial batch, and COA themselves.

Commercial risk also worsened in late 2026. GlobalSources no longer served the supplier profile, and Reddit users described post-payment non-delivery, including a claimed US$1,000 order and a separate Bitcoin-paid order with no staff response. The complaints are not verified transactions, but they are concrete enough to change prepayment risk.

Inside the full report:

  • Product pass/fail rates, trajectory plots, and methodology-divergence charts for all 11 tested products
  • Entity and domain chronology covering the Shenzhen capture, Yiwu address, GlobalSources removal, and 2026 site changes
  • DNS map of the storefront cluster, expired globalnwaozuo.com surface, and unresolved yiwuaozuopeptides.com placeholder
  • COA review comparing the stale 2025 gallery with public August 2026 Janoshik reports
  • Payment and fulfillment analysis covering Reddit complaints, crypto rails, Wise/Western Union, and refund contact path

Risk assessment

  • Order-fulfillment and after-sales risk — high: Oct. 2026 Reddit reports describe a claimed US$1,000 order and a separate large Bitcoin-paid order with no delivery and no staff response; unresolved as of the 2026-11-11 capture.
  • Corporate-identity and claims-accuracy risk — high: Aozuo claims 10+ years and GMP certification, but the verified domain/entity trail begins in 2024–2025 and no GMP certificate or facility audit evidence was found.
  • Product-specific quality risk — Sermorelin — high: Sermorelin is 35.58% with 0 pass / 3 fail in the Finnrick record; avoid unless the exact batch is independently tested before use.
  • Product-specific quality risk — BPC-157, Tesamorelin, TB-500 and Cagrilintide — medium: BPC-157 is 54.16%, Tesamorelin 50.08%, TB-500 51.85% and Cagrilintide 60.49%; this concern does not apply to Aozuo Tirzepatide or GHK-Cu.
  • Channel-authenticity and brand-confusion risk — medium: Multiple official-looking domains, an expired lookalike and an unresolved yiwuaozuopeptides.com placeholder exist without a vendor-published canonical-channel or authorized-reseller list.
  • Batch/COA verification risk — medium: The vendor certificate gallery is static at 2025 uploads, public 2026 Janoshik reports are not posted there, and no batch-to-vial lookup or signed COA workflow was found.